{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T01:55:05Z","timestamp":1768442105884,"version":"3.49.0"},"reference-count":38,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2016,6,28]],"date-time":"2016-06-28T00:00:00Z","timestamp":1467072000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100004963","name":"Seventh Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004963","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2017,1]]},"abstract":"Objectives<\/jats:title>We evaluated the virological response in patients starting a regimen based on darunavir\/ritonavir (DRV<\/jats:styled-content>\/r), which is currently the most widely used ritonavir\u2010boosted protease inhibitor.<\/jats:p><\/jats:sec>Methods<\/jats:title>Data from 206 drug\u2010na\u00efve and 327 PI<\/jats:styled-content>\u2010experienced patients starting DRV<\/jats:styled-content>\/r 600\/100\u00a0mg twice daily (DRV<\/jats:styled-content>600) or 800\/100\u00a0mg once daily (DRV<\/jats:styled-content>800) were examined. The probabilities of virological success (VS<\/jats:styled-content>) and virological rebound (VR<\/jats:styled-content>) were evaluated in survival analyses. Baseline DRV<\/jats:styled-content>\/r resistance and its evolution at failure were also examined.<\/jats:p><\/jats:sec>Results<\/jats:title>DRV<\/jats:styled-content>600 was preferentially administered in patients with complex requirements (older age, higher viraemia, lower CD<\/jats:styled-content>4 cell count and DRV<\/jats:styled-content>\/PI<\/jats:styled-content> resistance) compared with DRV<\/jats:styled-content>800. By 12\u00a0months, the probability of achieving VS<\/jats:styled-content> was 93.2% and 84.3% in drug\u2010na\u00efve and PI<\/jats:styled-content>\u2010experienced patients, respectively. The higher the baseline viraemia, the longer was the time required to achieve VS<\/jats:styled-content>, both in drug\u2010na\u00efve patients [>500\u00a0000 HIV<\/jats:styled-content>\u20101 RNA<\/jats:styled-content> copies\/mL<\/jats:styled-content>: median [interquartile range (IQR<\/jats:styled-content>)] 6.1 (5.1\u201310.3) months; 100\u00a0000\u2013500\u00a0000 copies\/mL<\/jats:styled-content>: median (IQR<\/jats:styled-content>) 4.9 (3.8\u20136.1) months; <100\u00a0000 copies\/mL<\/jats:styled-content>: median (IQR<\/jats:styled-content>) 3.9 (3.5\u20134.8) months; P<\/jats:italic>\u00a0<\u00a00.001] and in PI<\/jats:styled-content>\u2010experienced patients [\u2265100\u00a0000 copies\/mL<\/jats:styled-content>: median (IQR<\/jats:styled-content>) 7.2 (5.7\u201311.6) months; <100\u00a0000 copies\/mL<\/jats:styled-content>: median (IQR<\/jats:styled-content>) 2.8 (2.4\u20133.3) months; P<\/jats:italic>\u00a0<\u00a00.001]. In PI<\/jats:styled-content>\u2010experienced patients, the probability of VR<\/jats:styled-content> was higher for higher viraemia levels (22.3% for \u2265100\u00a0000 copies\/ml vs<\/jats:italic>. 9.7% for <100\u00a0000 copies\/mL; P<\/jats:italic>\u00a0=\u00a00.007). Baseline resistance did not affect the virological response. At failure, a high percentage of patients maintained virus susceptible to all PI<\/jats:styled-content>s (drug\u2010na\u00efve: 95%; PI<\/jats:styled-content>\u2010experienced: 80%). Despite being used more often in patients with more complex requirements, DRV<\/jats:styled-content>600 performed as well as DRV800.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>In clinical practice, use of DRV<\/jats:styled-content>\/r (with its flexible dosage) results in high rates of virological response. These data support the use of PI<\/jats:styled-content>\/r in patients whose characteristics require potent drugs with a high genetic barrier.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hiv.12388","type":"journal-article","created":{"date-parts":[[2016,6,29]],"date-time":"2016-06-29T16:19:15Z","timestamp":1467217155000},"page":"21-32","source":"Crossref","is-referenced-by-count":10,"title":["Virological response and resistance profile in HIV\u20101\u2010infected patients starting darunavir\u2010containing regimens"],"prefix":"10.1111","volume":"18","author":[{"given":"D","family":"Armenia","sequence":"first","affiliation":[{"name":"Experimental Medicine and Surgery University of Rome Tor Vergata Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Di Carlo","sequence":"additional","affiliation":[{"name":"Experimental Medicine and Surgery University of Rome Tor Vergata Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Maffongelli","sequence":"additional","affiliation":[{"name":"Infectious Diseases Division University Hospital Tor Vergata Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Borghi","sequence":"additional","affiliation":[{"name":"Infectious Diseases Division Modena University Hospital Modena Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Alteri","sequence":"additional","affiliation":[{"name":"Experimental Medicine and Surgery University of Rome Tor Vergata Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Forbici","sequence":"additional","affiliation":[{"name":"Antiretroviral Therapy Monitoring Unit L Spallanzani Hospital Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Bertoli","sequence":"additional","affiliation":[{"name":"Experimental Medicine and Surgery University of Rome Tor Vergata Rome Italy"},{"name":"Molecular Virology Division University Hospital Tor Vergata Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Gori","sequence":"additional","affiliation":[{"name":"Antiretroviral Therapy Monitoring Unit L Spallanzani Hospital Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Giuliani","sequence":"additional","affiliation":[{"name":"Infectious Dermatology Unit San Gallicano Hospital Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Nicastri","sequence":"additional","affiliation":[{"name":"Infectious Diseases Division L Spallanzani Hospital Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Zaccarelli","sequence":"additional","affiliation":[{"name":"Infectious Diseases Division L Spallanzani Hospital Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Pinnetti","sequence":"additional","affiliation":[{"name":"Infectious Diseases Division L Spallanzani Hospital Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Cicalini","sequence":"additional","affiliation":[{"name":"Infectious Diseases Division L Spallanzani Hospital Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"D'Offizi","sequence":"additional","affiliation":[{"name":"Infectious Diseases Division L Spallanzani Hospital Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Ceccherini\u2010Silberstein","sequence":"additional","affiliation":[{"name":"Experimental Medicine and Surgery University of Rome Tor Vergata Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Mussini","sequence":"additional","affiliation":[{"name":"Infectious Diseases Division Modena University Hospital Modena Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Antinori","sequence":"additional","affiliation":[{"name":"Infectious Diseases Division L Spallanzani Hospital Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Andreoni","sequence":"additional","affiliation":[{"name":"Infectious Diseases Division University Hospital Tor Vergata Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CF","family":"Perno","sequence":"additional","affiliation":[{"name":"Antiretroviral Therapy Monitoring Unit L Spallanzani Hospital Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MM","family":"Santoro","sequence":"additional","affiliation":[{"name":"Experimental Medicine and Surgery University of Rome Tor Vergata Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,6,28]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2009.10.003"},{"key":"e_1_2_6_3_1","unstructured":"Panel\u00a0on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV\u20101\u2010Infected Adults and Adolescents. Department of Health and Human Services.https:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/adultandadolescentgl.pdf(accessed 3 March 2016)."},{"key":"e_1_2_6_4_1","unstructured":"European AIDS Clinical Society Guidelines (EACS).Guidelines for the clinical management and treatment of HIV infected adults in Europe. Version 8.0. 2015.http:\/\/www.eacsociety.org\/files\/2015_eacsguidelines_8.0-english_revised-20151104.pdf(accessed 3 March 2016)."},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2012.681776"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.8722"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.7326\/M14-1084"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2012.01060.x"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.2174\/157016212799937218"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1301"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2736"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.17.4.19490"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60084-2"},{"key":"e_1_2_6_14_1","unstructured":"AntinoriA d'ArminioMonforte A GianottiNet\u00a0al.Post Authorization Non\u2010interventional Study including HIV1\u2010infected patients starting or already in treatment with darunavir\/ritonavir. 6th Italian Conference on AIDS and Retrovirusee (ICAR). Rome Italy May2014."},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku211"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjid.2012.08.022"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjid.2013.04.001"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2531"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.24017"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328345ee95"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12024"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku390"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu020"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2009.10.012"},{"key":"e_1_2_6_25_1","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1093\/jac\/dkv029","article-title":"HIV\u20101 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations also in patients with low\u2010level viremia","volume":"70","author":"Armenia D","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2007.0173"},{"key":"e_1_2_6_27_1","first-page":"132","article-title":"Update of the drug resistance mutations in HIV\u20101","volume":"23","author":"Wensing AM","year":"2015","journal-title":"Top Antivir Med"},{"key":"e_1_2_6_28_1","unstructured":"HIV\u2010Stanford\u2010Database. Protease Inhibitors (PI) Nucleo(t)side reverse transcriptase inhibitors (NRTI) nonNRTIs (NNRTI) and integrase inhibitors (INI) resistance Notes. Updated March 9 2015.http:\/\/hivdb.stanford.edu\/pages\/download\/resistanceMutations_handout.pdf"},{"key":"e_1_2_6_29_1","first-page":"195","article-title":"Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group","volume":"33","author":"Svicher V","year":"2010","journal-title":"New Microbiol"},{"key":"e_1_2_6_30_1","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1177\/135965350701200709","article-title":"Predicting HIV coreceptor usage on the basis of genetic and clinical covariates","volume":"12","author":"Sing T","year":"2007","journal-title":"Antivir Ther"},{"key":"e_1_2_6_31_1","first-page":"77","article-title":"European recommendations for the clinical use of HIV drug resistance testing: 2011 update","volume":"13","author":"Vandamme AM","year":"2011","journal-title":"AIDS Rev"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1086\/598502"},{"key":"e_1_2_6_33_1","unstructured":"KhatchatourianL HanfM JovelinT.et\u00a0al.Impact of Baseline Viral Load (VL) and Time to Viral Suppression on Subsequent Virologic Rebound (VR) According to First\u2010line Antiretroviral Therapy (cART). 15th European AIDS Conference. Barcelona Spain October2015."},{"key":"e_1_2_6_34_1","unstructured":"GourlayA FoxJ PhillipsAet\u00a0al.Time to Viral Suppression for HIV\u2010positive Patients Initiating cART with Very High Viraemia. 15th European AIDS Conference. Barcelona Spain October2015."},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq432"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181b17f53"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.17.4.19786"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2012.12.005"},{"key":"e_1_2_6_39_1","unstructured":"ArmeniaD GoriC DDi Carloet\u00a0al.HIV\u20101 CRF02_AG infected patients show a lower response to a PI based first line HAART: a role of specific natural polymorphisms. 15th European AIDS Conference. Barcelona Spain October 2015."}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhiv.12388","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhiv.12388","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.12388","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T16:39:57Z","timestamp":1695573597000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.12388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,28]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.1111\/hiv.12388"],"URL":"https:\/\/doi.org\/10.1111\/hiv.12388","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,28]]}}}